COMMUNIQUÉS West-GlobeNewswire

Picard Medical / SynCardia Showcases Leadership in Total Artificial Heart Therapy at Technology and Heart Failure Therapeutics Conference
02/03/2026
New data highlight additional benefits beyond survival with the SynCardia Total Artificial Heart and preclinical progress for the next-generation Emperor system TUCSON, Ariz., March 02, 2026 (GLOBE NEWSWIRE) -- Picard [...]
Humacyte To Participate in Upcoming Investor Conferences
02/03/2026
DURHAM, N.C., March 02, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, [...]
FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis
02/03/2026
HOUSTON, March 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the [...]
CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting
02/03/2026
MINNEAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with [...]
Galecto to Participate in Leerink Partners 2026 Global Healthcare Conference
02/03/2026
BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that company management will participate [...]
Artios Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer
02/03/2026
Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone in patients with platinum-resistant high-grade serous ovarian cancer Study provides additional [...]
Oncolytics Biotech® Launches Randomized Colorectal Cancer Study
02/03/2026
Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026 Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRAS-mutant MSS [...]
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
02/03/2026
Commercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales in 2025 were $15.8 [...]
Imviva Biotech Announces Acceptance of Late-Breaking Abstract Highlighting Data from Ongoing Phase 1/2 Study of CTA313 at 15th European Lupus Meeting
02/03/2026
Novel allogeneic CAR-T therapy demonstrates durable remission and immune-reset mechanism in systemic lupus erythematosus BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company [...]
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
02/03/2026
Encouraging data for CAD-1005 in Phase 2 HIT Study EOP2 scheduled for Q1 for top-priority indication Additional acute and chronic opportunities for 12-LOX inhibition beyond HIT PONTE VEDRA, Fla., March 02, 2026 (GLOBE [...]
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)
02/03/2026
-- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with iovera º for patients with osteoarthritis (OA) of the knee -- -- Data presented at the American [...]
Biomimetic Innovations Ltd Announces Upcoming Clinical Study of OsStic™ Injectable Synthetic Bone Void Filler in Tibial Plateau Fracture Fixation
02/03/2026
SHANNON, Ireland, March 02, 2026 (GLOBE NEWSWIRE) -- Biomimetic Innovations Ltd, an affiliate of PBC Biomed, an Irish medical device company specialising in biomimetic materials, today announced approval by MHRA for a [...]
Evaxion to announce business update and full year 2025 financial results on March 5, 2026
02/03/2026
COPENHAGEN, Denmark, March 2, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and [...]
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
02/03/2026
COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a virtual fireside chat at the TD Cowen 46th Annual Health Care [...]
NewGen Signs MOU with Women in Web3 Hong Kong to Launch Regional Women’s Health Awareness Initiative
02/03/2026
BANGKOK, March 02, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group (NASDAQ: NIVF) (“NewGen” or the “Company”), a technology-driven, diversified growth company, today announced that it has entered into a Memorandum of [...]
Replimune to Present at Two Upcoming Investor Conferences
02/03/2026
WOBURN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members [...]
Health Catalyst to Announce Fourth Quarter and Year End 2025 Operating Results and Host Conference Call on Thursday, March 12, 2026
02/03/2026
SALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its [...]
Award-Winning Speaker Mike Veny Launches “Coffee with Mike” Mental Health Podcast for Workplace Leaders
02/03/2026
New podcast explores employee wellness, workplace mental health, and belonging strategies for leaders and organizations NEW YORK, New York, March 02, 2026 (GLOBE NEWSWIRE) -- Lovely Refinement CEO and mental health [...]
Tilray Brands Acquires BrewDog, a Leading Global Craft Brand, Creating a ~$500 Million Global Craft Beer and Beverage Platform
02/03/2026
Accretive Acquisition of Select Assets Includes Global Brand, UK Brewing Operations and 11 Strategic Brewpubs Expected to Generate ~$200 Million in Annual Net Revenue and ~$6 - $8 Million of Adjusted EBITDA in Fiscal [...]

Pages